Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLTX-CAR T Cells for MMP2+ Recurrent or Progressive Glioblastoma
NCT04214392Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2020
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CHM-1101 in glioblastoma (GBM) and malignant glioma (2 arms), sponsored by City of Hope. Primary endpoint: Dose Limiting Toxicity at 28 days. Started May 2020; status: active, not recruiting.
02
Drugs
CHM-1101
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT04214392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214392.